Aaron B. Waxman, MD, PhD
Assistant Professor of Medicine, Harvard Medical School
Director, Pulmonary Vascular Disease Program
Brigham and Women’s Hospital
Clinical Case Challenge (Online)
Pulmonary Arterial Hypertension (PAH) comprises a group of diseases characterized by vascular proliferation and a progressive increase in pulmonary vascular resistance that ultimately leads to right ventricular failure and early mortality. Three classes of drugs (prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors) have been approved for the treatment of PAH. Still more clinical trials are being conducted to examine promising new therapies, and PAH guidelines are being revised for existing therapies. Clinicians are struggling to integrate this wave of new therapies and research into effective evidence-based guidelines. Since PAH is such a heterogeneous and relatively uncommon disorder, patients’ unique clinical histories and their specific form of PAH must be taken into account when selecting a treatment strategy.
Clinicians may have difficulty evaluating patients with PAH because they are not aware of the latest advances in diagnosis and patient monitoring. Once a diagnosis is made, clinicians ought to be tailoring treatments based on the patient’s PAH classification. Many clinicians do not have a strong understanding of the mechanisms of action and possible adverse events of the available treatments. To address these gaps, this continuing education program aims to increase physicians' awareness of the indicators of PAH, how to evaluate and diagnosis PAH, choices of therapy to optimize patient outcomes, and current best practices in patient monitoring.
Jointly Provided by the University of California, Irvine School of Medicine and
MCM Education Target Audience
Designed for pulmonologists, cardiologists, and critical care specialists interested in the treatment of patients with pulmonary arterial hypertension.
Upon completion of this educational activity, the participant should be able to:
Identify some of the major challenges associated with the evaluation and diagnosis of PAH.
Describe how treatment strategies may impact the clinical course for patients with PAH.
It is the policy of the University of California, Irvine School of Medicine and the University of California CME Consortium to ensure balance, independence, objectivity and scientific rigor in all CME activities. Full disclosure of conflict resolution can be found below.
Dr. Waxman discloses that he is steering committees for Gilead and Medtronic; receives research funding from Bayer, Gilead, and United Therapeutics; and is a scientific advisor to Pfizer and United Therapeutics, which could be perceived as a potential conflict of interest in this presentation. Dr. Waxman has disclosed that based on his potential conflict of interest his presentation has been peer reviewed for evidence base and fair balance.
In accordance with the ACCME Essential Areas and policies regarding commercial support, the audience is advised that the following faculty will discuss unlabeled or unapproved uses of drugs or devices.
Dr. Waxman’s presentation does not include discussion of off-label, experimental, and/or investigational uses of treatments of patients with pulmonary arterial hypertension.
Conflict Resolution: All presentations have been peer reviewed for evidence base and fair balance.
The CME Office Staff of the University of California, Irvine School of Medicine and Medical Communications Media, Inc. have nothing to disclose. The Peer Reviewer, Dr. Samuel Wilson, MD, has disclosed he has no relationships with any commercial entity. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Irvine School of Medicine or Medical Communications Media, Inc. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of California, Irvine School of Medicine and Medical Communications Media, Inc. The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The University of California, Irvine School of Medicine designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
California Assembly Bill 1195
This activity is in compliance with California Assembly Bill 1195, which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. For specific information regarding Bill 1195 and definitions of cultural and linguistic competency, please visit the CME website: http://www.meded.uci.edu/CME/CME-H-AB1195.htm.
Commercial Support Statements
© 2010, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of California, Irvine, Actelion Pharmaceuticals, or Gilead. Any medications, diagnostic procedures, or treatments discussed by the program faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.